

Charles L. Hyman, M.D.
Director
Regulatory Affairs

Merck & Co., Inc.
P.O. Box 4
West Point PA 19486
Fax 610 397 2516
Tel 610 397 2850
215 652 5000

May 20, 1998

DESK COPY

Dr. H. W. Ju
Division of Scientific Investigations Clinical Branch
HFD-344, Room 125
Food and Drug Administration
7520 Standish Place
Rockville, Maryland 20855



Dear Dr. Ju:

**NDA 19-643/S-055
MEVACOR™ (Lovastatin)**

RESPONSE TO REQUEST FOR INFORMATION

Reference is made to the above Supplemental New Drug Application (SNDA) submitted on April 28, 1998. Reference is also made to telephone conversations between Dr. H. W. Ju, Division of Scientific Investigations (DSI) and Dr. Charles L. Hyman, Merck Research Laboratories (MRL) on May 15 and 19, 1998. During these conversations, Dr. Ju requested the following information regarding the Lovastatin - Air Force/Texas Coronary Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) SNDA/S-055: name and address of primary investigator, number of patients enrolled at each site, number of patients completed at each site, address of sites, a copy of the original protocol, copies of the cover letters for each protocol amendment, and a copy of the summary volume.

With this letter and attachments, MRL is providing the requested information. The only study in this submission is AFCAPS/TexCAPS (Protocol 042) which is entitled, "A Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Lovastatin on the Incidence of Primary Coronary Heart Disease in Patients With Mild to Moderate Elevations in Total and LDL-Cholesterol in Combination with Low HDL-Cholesterol".

The study site number is 042-001. The study is a single site study with two clinical locations in the United States. The primary investigator for this study is John R. Downs, M.D., AFCAPS Clinic, Lackland Air Force Base, Wilford Hall Medical Center (WHMC), San Antonio, TX 78236-5316. Michael Clearfield, D.O., and Stephen Weis, D.O. are subinvestigators for this study at the TexCAPS Clinic, University of North Texas, Health Sciences Center, Fort Worth, TX 76107 location.

Dr. H. W. Ju
NDA 19-643/S-055
MEVACOR™ (Lovastatin)
RESPONSE TO REQUEST FOR INFORMATION
Page 2

The following chart contains the number of patients enrolled and completed at each clinic location:

Clinic Location	No. of Patients Enrolled	No. of Patients Completed
John R. Downs, M.D. Primary Investigator AFCAPS Clinic Lackland Air Force Base, Wilford Hall Medical Center (WHMC), San Antonio, TX 78236-5316	3737	2482
Michael Clearfield, D.O. Stephen Weis, D.O. Subinvestigators TexCAPS Clinic University of North Texas Health Science Center Fort Worth, Texas 76107	2868	1934


A copy of the original protocol and copies of the cover letters for each protocol amendment for Protocol 042 is attached (Attachment 1). As this submission is based on one study, there is no summary volume. Enclosed is a copy of the of the Synopsis and Comprehensive Study Summary for Protocol 042 (Attachment 2).

We consider the filing of this Supplemental New Drug Application to be a confidential matter, and request the Food and Drug Administration not make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc.

Dr. H. W. Ju
NDA 19-643/S-055
MEVACOR™ (Lovastatin)
RESPONSE TO REQUEST FOR INFORMATION
Page 3

Questions concerning this information should be directed to Charles L. Hyman, M.D. (610/397-2850) or, in my absence, to Robert E. Silverman, M.D., Ph.D. (610/397-2944).

Sincerely,



Charles L. Hyman, M.D.
Director, Regulatory Affairs

Attachment

Federal Express #1

Desk Copies (cover letter only)

Ms. Margaret Simoneau, HFD-510, Rm. 14B-04, Federal Express #2

FDA File: FDA 19-643 / S-055: MEVACOR™ (Lovastatin), Dr. Sobel,
HFD-510, Rm. 14B-04, Federal Express #2

Charles L. Hyman, M.D.
Director
Regulatory Affairs

Merck & Co., Inc.
P.O. Box 4
West Point PA 19486
Fax 610 397 2516
Tel 610 397 2850
215 652 5000

May 19, 1998



Ms. Margaret Simoneau
Senior Regulatory Manager
Division of Metabolism and Endocrine
Drug Products HFD-510, Room 14B-04
Office of Drug Evaluation II (CDER)
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

NDA 19-643/S-055: MEVACOR™ (Lovastatin)

Lovastatin - AFCAPS/TexCAPS

Dear Ms. Simoneau:

Reference is made to the above Supplemental New Drug Application (sNDA/S-055), Lovastatin-AFCAPS/TexCAPS, contained in the Compact Disk (CD) delivered to Mr. David M. Moss, Director, Technology Support Service Staff (TSSS) on May 12, 1998 with the hard copy submitted to the Agency on April 28, 1998.


Enclosed are five (5) copies of the User Manual for the Document Access Component of the Electronic Submission for the complete sNDA to be distributed to the reviewers from the Division of Metabolism and Endocrine Drug Products. These manuals also contain two supplementary User Guides to assist in the location within the text-based Case Report Forms.

We consider the information included in this submission to be a confidential matter, and request that the Food and Drug Administration not make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc.

Ms. Margaret Simoneau
NDA 19-643/S-055: MEVACOR™ (Lovastatin)
Lovastatin - AFCAPS/TexCAPS
Page 2

If you have any questions or need additional information contact Charles Hyman, M.D.,
(610) 397-2850 or, in my absence, Marie Dray (301) 881-9000.

Sincerely,



Charles L. Hyman, M.D.
Director
Regulatory Affairs

Federal Express #1

Attachments: 5 User Manuals

Desk Copy: ~~Dr. D. Orloff, HFD-510, Room 14B04, Federal Express #1~~
~~Dr. W. Berlin, HFD-510, Room 14B31, Federal Express #1~~
~~Dr. R. Steigerwalt, HFD-510, Room 14B04, Federal Express #1~~
~~Dr. J. Mele, HFD-715, Room 14B45, Federal Express #2~~

Official Submission HFD-510
NDA File 19-643 (2 copies) letter only Federal Express #1

q\robinson\murakami\afxcaps

Larry P. Bell, M.D.
Senior Director
Regulatory Affairs

Merck & Co., Inc.
P.O. Box 4, BLA-20
West Point PA 19486
Fax 610 397 2516
Tel 610 397 2310
215 652 5000
Email larry_bell@merck.com

May 12, 1998

Mr. David M. Moss
Director, Technology Support Service Staff
Center for Drug Evaluation & Research
Food & Drug Administration
5600 Fishers Lane, 8B-11
Rockville, Maryland 20857



Supplemental New Drug Application

**NDA 19-643: Tablets MEVACOR™ (Lovastatin)
Lovastatin - AFCAPS/TexCAPS**

Dear Mr. Moss:

By copy of this letter, Merck Research Laboratories (MRL) is providing to the Technology Support Service Staff (TSSS) one (1) Compact Disk (CD) which contains the Supplemental New Drug Application (sNDA) for NDA 19-643 MEVACOR™ (Lovastatin), AFCAPS/TexCAPS, submitted in hardcopy on April 28, 1998.

The information on the CD [REDACTED] is to be copied to the [REDACTED] currently installed on the MRL-dedicated network server in use at the Agency for the NDA 19-766 ZOCOR™ (Simvastatin) Original New Drug Application disk labeled MK733 electronic submission.

The reviewers identified by the Endocrine & Metabolic Drug Products Division and the Division of Biometrics who should be provided access to the electronic submission from their desktops are as follows:

Dr. David Orloff	HFD-510	PKLN 14B04
Dr. William Berlin	HFD-510	PKLN 14B31
Dr. Ronald Steigerwalt	HFD-510	PKLN 14B04
Dr. Joy D. Mele	HFD-715	PKLN 14B45

Please notify MRL's Regulatory Agency Relations (RAR) Office (301/881-9000) when the disk installations are successfully completed and access from the reviewers' desktops is functional.

When an action has been taken on this submission and the CD is no longer needed, MRL will make arrangements to retrieve them from the FDA. We understand that, in the future, information submitted in electronic form may be retained indefinitely by the Agency, as an archival copy of the application, in the event that a complete paper submission is not filed.

Mr. David M. Moss
Director, Technology Support Services Staff
NDA 19-643: Tablets MEVACOR™
Supplemental New Drug Application
Lovastatin - AFCAPS/TexCAPS


We have taken precautions to ensure that any software on the CD is free of computer viruses and we authorize the use of anti-virus software, as appropriate.

There are five attachments to this letter:

- Attachment 1 An sNDA Table of Contents of the accompanying electronic submission.
- Attachment 2 A Difference Report identifying differences between the electronic version of this submission and the hard copy submission.
- Attachment 3 Installation Instructions detailing how to copy the contents of the CD onto the server.
- Attachment 4 Documentation regarding the development procedures performed at MRL for this electronic submission.
- Attachment 5 A complete list of file names.

During the time that the electronic submission is actively being used, MRL will provide technical support. Any questions relating to this electronic submission should be addressed to me (610/397-2310) or, in my absence, Marie Dray (301/881-9000).

Sincerely,



Larry Bell, M.D.
Senior Director, Regulatory Affairs

Attachments
Enclosures:
Compact Disks (CD)



Federal Express #1

APPEARS THIS WAY ON ORIGINAL